カテゴリー： LP Information, 医療/バイオ

ドルテグラビル/リルピビリン配合薬の世界市場予測2019年-2024年

【英語タイトル】Global Dolutegravir/Rilpivirine Combination Drug Market Growth 2019-2024

LP Informationが出版した調査資料（LPI9070716）・商品コード：LPI9070716
・発行会社（調査会社）：LP Information
・発行日：2019年8月9日
・ページ数：130
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single UserUSD3,660 ⇒換算￥380,640見積依頼/購入/質問フォーム
Multi UserUSD5,490 ⇒換算￥570,960見積依頼/購入/質問フォーム
Corporate UserUSD7,320 ⇒換算￥761,280見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
「ドルテグラビル/リルピビリン配合薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、自社製造API、アウトソーシングAPIなど、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。ドルテグラビル/リルピビリン配合薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。
・ドルテグラビル/リルピビリン配合薬の世界市場概要（サマリー）
・ドルテグラビル/リルピビリン配合薬の企業別販売量・売上
・ドルテグラビル/リルピビリン配合薬の企業別市場シェア
・ドルテグラビル/リルピビリン配合薬の世界市場規模：種類別（自社製造API、アウトソーシングAPI）
・ドルテグラビル/リルピビリン配合薬の世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他）
・ドルテグラビル/リルピビリン配合薬の米州市場規模（アメリカ、カナダ、メキシコなど）
・ドルテグラビル/リルピビリン配合薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）
・ドルテグラビル/リルピビリン配合薬の欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・ドルテグラビル/リルピビリン配合薬の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）
・ドルテグラビル/リルピビリン配合薬市場の成長要因・課題・動向
・ドルテグラビル/リルピビリン配合薬の販売チャネル、流通業者、顧客
・ドルテグラビル/リルピビリン配合薬の世界市場予測
・ドルテグラビル/リルピビリン配合薬の米州市場予測（アメリカ、カナダ、メキシコなど）
・ドルテグラビル/リルピビリン配合薬のアジア市場予測（日本、中国、韓国、インド、東南アジアなど）
・ドルテグラビル/リルピビリン配合薬の欧州市場予測（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・ドルテグラビル/リルピビリン配合薬の中東・アフリカ市場予測（エジプト、南アフリカ、トルコ、GCC諸国など）
・ドルテグラビル/リルピビリン配合薬の世界市場予測：種類別（自社製造API、アウトソーシングAPI）
・ドルテグラビル/リルピビリン配合薬の世界市場予測：用途別（病院、クリニック、ドラッグセンター、その他）
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Dolutegravir/Rilpivirine Combination Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Dolutegravir/Rilpivirine Combination Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Dolutegravir/Rilpivirine Combination Drug market by product type, application, key manufacturers and key regions and countries.

This study considers the Dolutegravir/Rilpivirine Combination Drug value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Self-production API
Outsourcing of API
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Drug Center
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
ViiV Healthcare
JNJ
…

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Dolutegravir/Rilpivirine Combination Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Dolutegravir/Rilpivirine Combination Drug market by identifying its various subsegments.
Focuses on the key global Dolutegravir/Rilpivirine Combination Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Dolutegravir/Rilpivirine Combination Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Dolutegravir/Rilpivirine Combination Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

Table of Contents

2019-2024 Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dolutegravir/Rilpivirine Combination Drug Consumption 2014-2024
2.1.2 Dolutegravir/Rilpivirine Combination Drug Consumption CAGR by Region
2.2 Dolutegravir/Rilpivirine Combination Drug Segment by Type
2.2.1 Self-production API
2.2.2 Outsourcing of API
2.3 Dolutegravir/Rilpivirine Combination Drug Consumption by Type
2.3.1 Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
2.3.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue and Market Share by Type (2014-2019)
2.3.3 Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Type (2014-2019)
2.4 Dolutegravir/Rilpivirine Combination Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Drug Center
2.4.4 Other
2.5 Dolutegravir/Rilpivirine Combination Drug Consumption by Application
2.5.1 Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
2.5.2 Global Dolutegravir/Rilpivirine Combination Drug Value and Market Share by Application (2014-2019)
2.5.3 Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Application (2014-2019)

3 Global Dolutegravir/Rilpivirine Combination Drug by Manufacturers
3.1 Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers
3.1.1 Global Dolutegravir/Rilpivirine Combination Drug Sales by Manufacturers (2017-2019)
3.1.2 Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers (2017-2019)
3.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Manufacturers
3.2.1 Global Dolutegravir/Rilpivirine Combination Drug Revenue by Manufacturers (2017-2019)
3.2.2 Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Manufacturers (2017-2019)
3.3 Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Manufacturers
3.4 Global Dolutegravir/Rilpivirine Combination Drug Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
3.4.1 Global Dolutegravir/Rilpivirine Combination Drug Manufacturing Base Distribution and Sales Area by Manufacturers
3.4.2 Players Dolutegravir/Rilpivirine Combination Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Dolutegravir/Rilpivirine Combination Drug by Regions
4.1 Dolutegravir/Rilpivirine Combination Drug by Regions
4.1.1 Global Dolutegravir/Rilpivirine Combination Drug Consumption by Regions
4.1.2 Global Dolutegravir/Rilpivirine Combination Drug Value by Regions
4.2 Americas Dolutegravir/Rilpivirine Combination Drug Consumption Growth
4.3 APAC Dolutegravir/Rilpivirine Combination Drug Consumption Growth
4.4 Europe Dolutegravir/Rilpivirine Combination Drug Consumption Growth
4.5 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Growth

5 Americas
5.1 Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Countries
5.1.1 Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019)
5.1.2 Americas Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019)
5.2 Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Type
5.3 Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Countries
6.1.1 APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019)
6.1.2 APAC Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019)
6.2 APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Type
6.3 APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Dolutegravir/Rilpivirine Combination Drug by Countries
7.1.1 Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019)
7.1.2 Europe Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019)
7.2 Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Type
7.3 Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug by Countries
8.1.1 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019)
8.1.2 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019)
8.2 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Type
8.3 Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Dolutegravir/Rilpivirine Combination Drug Distributors
10.3 Dolutegravir/Rilpivirine Combination Drug Customer

11 Global Dolutegravir/Rilpivirine Combination Drug Market Forecast
11.1 Global Dolutegravir/Rilpivirine Combination Drug Consumption Forecast (2019-2024)
11.2 Global Dolutegravir/Rilpivirine Combination Drug Forecast by Regions
11.2.1 Global Dolutegravir/Rilpivirine Combination Drug Forecast by Regions (2019-2024)
11.2.2 Global Dolutegravir/Rilpivirine Combination Drug Value Forecast by Regions (2019-2024)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Dolutegravir/Rilpivirine Combination Drug Forecast by Type
11.8 Global Dolutegravir/Rilpivirine Combination Drug Forecast by Application

12 Key Players Analysis
12.1 ViiV Healthcare
12.1.1 Company Details
12.1.2 Dolutegravir/Rilpivirine Combination Drug Product Offered
12.1.3 ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Sales, Revenue, Price and Gross Margin (2017-2019)
12.1.4 Main Business Overview
12.1.5 ViiV Healthcare News
12.2 JNJ
12.2.1 Company Details
12.2.2 Dolutegravir/Rilpivirine Combination Drug Product Offered
12.2.3 JNJ Dolutegravir/Rilpivirine Combination Drug Sales, Revenue, Price and Gross Margin (2017-2019)
12.2.4 Main Business Overview
12.2.5 JNJ News
…

13 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of Dolutegravir/Rilpivirine Combination Drug
Table Product Specifications of Dolutegravir/Rilpivirine Combination Drug
Figure Dolutegravir/Rilpivirine Combination Drug Report Years Considered
Figure Market Research Methodology
Figure Global Dolutegravir/Rilpivirine Combination Drug Consumption Growth Rate 2014-2024 (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Value Growth Rate 2014-2024 ($ Millions)
Table Dolutegravir/Rilpivirine Combination Drug Consumption CAGR by Region 2014-2024 ($ Millions)
Figure Product Picture of Self-production API
Table Major Players of Self-production API
Figure Product Picture of Outsourcing of API
Table Major Players of Outsourcing of API
Table Global Consumption Sales by Type (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Revenue by Type (2014-2019) ($ million)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Type (2014-2019) ($ Millions)
Figure Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Type (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Type (2014-2019)
Figure Dolutegravir/Rilpivirine Combination Drug Consumed in Hospital
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Hospital (2014-2019) (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Hospital (2014-2019) ($ Millions)
Figure Dolutegravir/Rilpivirine Combination Drug Consumed in Clinic
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Clinic (2014-2019) (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Clinic (2014-2019) ($ Millions)
Figure Dolutegravir/Rilpivirine Combination Drug Consumed in Drug Center
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Drug Center (2014-2019) (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Drug Center (2014-2019) ($ Millions)
Figure Dolutegravir/Rilpivirine Combination Drug Consumed in Other
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Other (2014-2019) (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Market: Other (2014-2019) ($ Millions)
Table Global Consumption Sales by Application (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Value by Application (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Application (2014-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Application (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Application (2014-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Sales by Manufacturers (2017-2019) (K Pcs)
Table Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers (2017-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers in 2017
Figure Global Dolutegravir/Rilpivirine Combination Drug Sales Market Share by Manufacturers in 2018
Table Global Dolutegravir/Rilpivirine Combination Drug Revenue by Manufacturers (2017-2019) ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Manufacturers (2017-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Manufacturers in 2017
Figure Global Dolutegravir/Rilpivirine Combination Drug Revenue Market Share by Manufacturers in 2018
Table Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Manufacturers (2017-2019)
Figure Global Dolutegravir/Rilpivirine Combination Drug Sale Price by Manufacturers in 2018
Table Global Dolutegravir/Rilpivirine Combination Drug Manufacturing Base Distribution and Sales Area by Manufacturers
Table Players Dolutegravir/Rilpivirine Combination Drug Products Offered
Table Dolutegravir/Rilpivirine Combination Drug Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Regions 2014-2019
Figure Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Regions 2014-2019
Table Global Dolutegravir/Rilpivirine Combination Drug Value by Regions 2014-2019 ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Regions 2014-2019
Figure Global Dolutegravir/Rilpivirine Combination Drug Value Market Share by Regions 2014-2019
Figure Americas Dolutegravir/Rilpivirine Combination Drug Consumption 2014-2019 (K Pcs)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Value 2014-2019 ($ Millions)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Consumption 2014-2019 (K Pcs)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Value 2014-2019 ($ Millions)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Consumption 2014-2019 (K Pcs)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Value 2014-2019 ($ Millions)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption 2014-2019 (K Pcs)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value 2014-2019 ($ Millions)
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019) (K Pcs)
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries (2014-2019)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries in 2018
Table Americas Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019) ($ Millions)
Table Americas Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries (2014-2019)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries in 2018
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Type (2014-2019) (K Pcs)
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type in 2018
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption by Application (2014-2019) (K Pcs)
Table Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application in 2018
Figure United States Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure United States Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Canada Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Canada Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Mexico Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Mexico Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019) (K Pcs)
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries (2014-2019)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries in 2018
Table APAC Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019) ($ Millions)
Table APAC Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries (2014-2019)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries in 2018
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Type (2014-2019) (K Pcs)
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type in 2018
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption by Application (2014-2019) (K Pcs)
Table APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application in 2018
Figure China Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure China Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Japan Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Japan Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Korea Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Korea Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Southeast Asia Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Southeast Asia Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure India Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure India Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Australia Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Australia Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019) (K Pcs)
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries (2014-2019)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries in 2018
Table Europe Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019) ($ Millions)
Table Europe Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries (2014-2019)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries in 2018
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Type (2014-2019) (K Pcs)
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type in 2018
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption by Application (2014-2019) (K Pcs)
Table Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application in 2018
Figure Germany Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Germany Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure France Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure France Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure UK Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure UK Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Italy Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Italy Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Russia Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Russia Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Spain Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Spain Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Countries (2014-2019) (K Pcs)
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries (2014-2019)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Countries in 2018
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value by Countries (2014-2019) ($ Millions)
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries (2014-2019)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value Market Share by Countries in 2018
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Type (2014-2019) (K Pcs)
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type (2014-2019)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Type in 2018
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption by Application (2014-2019) (K Pcs)
Table Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application (2014-2019)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption Market Share by Application in 2018
Figure Egypt Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Egypt Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure South Africa Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure South Africa Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Israel Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Israel Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure Turkey Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure Turkey Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Figure GCC Countries Dolutegravir/Rilpivirine Combination Drug Consumption Growth 2014-2019 (K Pcs)
Figure GCC Countries Dolutegravir/Rilpivirine Combination Drug Value Growth 2014-2019 ($ Millions)
Table Dolutegravir/Rilpivirine Combination Drug Distributors List
Table Dolutegravir/Rilpivirine Combination Drug Customer List
Figure Global Dolutegravir/Rilpivirine Combination Drug Consumption Growth Rate Forecast (2019-2024) (K Pcs)
Figure Global Dolutegravir/Rilpivirine Combination Drug Value Growth Rate Forecast (2019-2024) ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Forecast by Countries (2019-2024) (K Pcs)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Forecast by Regions
Table Global Dolutegravir/Rilpivirine Combination Drug Value Forecast by Countries (2019-2024) ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share Forecast by Regions
Figure Americas Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Americas Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure APAC Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Europe Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Middle East & Africa Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure United States Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure United States Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Canada Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Canada Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Mexico Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Mexico Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Brazil Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Brazil Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure China Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure China Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Japan Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Japan Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Korea Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Korea Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Southeast Asia Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Southeast Asia Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure India Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure India Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Australia Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Australia Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Germany Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Germany Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure France Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure France Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure UK Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure UK Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Italy Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Italy Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Russia Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Russia Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Spain Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Spain Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Egypt Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Egypt Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure South Africa Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure South Africa Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Israel Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Israel Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure Turkey Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure Turkey Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Figure GCC Countries Dolutegravir/Rilpivirine Combination Drug Consumption 2019-2024 (K Pcs)
Figure GCC Countries Dolutegravir/Rilpivirine Combination Drug Value 2019-2024 ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Forecast by Type (2019-2024) (K Pcs)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share Forecast by Type (2019-2024)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Forecast by Type (2019-2024) ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share Forecast by Type (2019-2024)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Forecast by Application (2019-2024) (K Pcs)
Table Global Dolutegravir/Rilpivirine Combination Drug Consumption Market Share Forecast by Application (2019-2024)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Forecast by Application (2019-2024) ($ Millions)
Table Global Dolutegravir/Rilpivirine Combination Drug Value Market Share Forecast by Application (2019-2024)
Table ViiV Healthcare Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Sales, Revenue, Price and Gross Margin (2017-2019)
Figure ViiV Healthcare Dolutegravir/Rilpivirine Combination Drug Market Share (2017-2019)
Table JNJ Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table JNJ Dolutegravir/Rilpivirine Combination Drug Sales, Revenue, Price and Gross Margin (2017-2019)
Figure JNJ Dolutegravir/Rilpivirine Combination Drug Market Share (2017-2019)


★調査レポート[ドルテグラビル/リルピビリン配合薬の世界市場予測2019年-2024年] (コード：LPI9070716)販売に関する免責事項を必ずご確認ください。
★調査レポート[ドルテグラビル/リルピビリン配合薬の世界市場予測2019年-2024年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の世界市場予測2019年-2024年
    LPI9072231 / LP Information / 2019年8月20日 / 「テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、10、30など、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。テノホビル/ラミブジン/アタザナビル/リトナビル配合薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の世界市場概要（サマリー） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の企業別販売量・売上 ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の企業別市場シェア ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の世界市場規模：種類別（10、30） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の米州市場規模（アメリカ、カナダ、メキシコなど） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・テノホビル/ラミブジン/アタザナビル/リトナビル配合薬の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug market by product type, application, key manufacturers and key regions and countries. This study considers the Tenofovir/Lamivudine/Atazanavir/Ritonavir Combination Drug value...
  • エムトリシタビン/リルピビリン/テノホビルアラフェナミドの世界市場予測2019年-2024年
    LPI9070806 / LP Information / 2019年8月9日 / 「エムトリシタビン/リルピビリン/テノホビルアラフェナミドの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、自社製造API、アウトソーシングAPIなど、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。エムトリシタビン/リルピビリン/テノホビルアラフェナミドのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの世界市場概要（サマリー） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの企業別販売量・売上 ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの企業別市場シェア ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの世界市場規模：種類別（自社製造API、アウトソーシングAPI） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの米州市場規模（アメリカ、カナダ、メキシコなど） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドのアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・エムトリシタビン/リルピビリン/テノホビルアラフェナミドの中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Emtricitabine/Rilpivirine/Tenofovir Alafenamide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Emtricitabine/Rilpivirine/Tenofovir Alafenamide business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Emtricitabine/Rilpivirine/Tenofovir Alafenamide market by product type, application, key manufacturers and key regions and countries. This study considers the Emtricitabine/Rilpivirine/Tenofovir Alafenamide value and volume generated from...
  • テノホビル/エムトリシタビン配合剤の世界市場予測2019年-2024年
    LPI9072230 / LP Information / 2019年8月20日 / 「テノホビル/エムトリシタビン配合剤の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、自己制作API、APIアウトソーシングなど、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。テノホビル/エムトリシタビン配合剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・テノホビル/エムトリシタビン配合剤の世界市場概要（サマリー） ・テノホビル/エムトリシタビン配合剤の企業別販売量・売上 ・テノホビル/エムトリシタビン配合剤の企業別市場シェア ・テノホビル/エムトリシタビン配合剤の世界市場規模：種類別（自己制作API、APIアウトソーシング） ・テノホビル/エムトリシタビン配合剤の世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・テノホビル/エムトリシタビン配合剤の米州市場規模（アメリカ、カナダ、メキシコなど） ・テノホビル/エムトリシタビン配合剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・テノホビル/エムトリシタビン配合剤の欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・テノホビル/エムトリシタビン配合剤の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Tenofovir/Emtricitabine Combination Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tenofovir/Emtricitabine Combination Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tenofovir/Emtricitabine Combination Drug market by product type, application, key manufacturers and key regions and countries. This study considers the Tenofovir/Emtricitabine Combination Drug value...
  • エファビレンツ/テノフォビル/エムトリシタビン配合剤の世界市場予測2019年-2024年
    LPI9070758 / LP Information / 2019年8月9日 / 「エファビレンツ/テノフォビル/エムトリシタビン配合剤の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、10タブレット、 30タブレットなど、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。エファビレンツ/テノフォビル/エムトリシタビン配合剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の世界市場概要（サマリー） ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の企業別販売量・売上 ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の企業別市場シェア ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の世界市場規模：種類別（10タブレット、 30タブレット） ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・エファビレンツ/テノフォビル/エムトリシタビン配合剤の米州市場規模（アメリカ、カナダ、メキシコなど） ・エファビレンツ/テノフォビル/エムトリシタビン配合剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）... According to this study, over the next five years the Efavirenz/Tenofovir/Emtricitabine Combination Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Efavirenz/Tenofovir/Emtricitabine Combination Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Efavirenz/Tenofovir/Emtricitabine Combination Drug market by product type, application, key manufacturers and key regions and countries. This study considers the Efavirenz/Tenofovir/Emtricitabine Combination Drug value...
  • リルピビリンの世界市場予測2019年-2024年
    LPI9071964 / LP Information / 2019年8月16日 / 「リルピビリンの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、自己生産API、APIアウトソーシングなど、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。リルピビリンのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・リルピビリンの世界市場概要（サマリー） ・リルピビリンの企業別販売量・売上 ・リルピビリンの企業別市場シェア ・リルピビリンの世界市場規模：種類別（自己生産API、APIアウトソーシング） ・リルピビリンの世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・リルピビリンの米州市場規模（アメリカ、カナダ、メキシコなど） ・リルピビリンのアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・リルピビリンの欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・リルピビリンの中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Rilpivirine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Rilpivirine business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Rilpivirine market by product type, application, key manufacturers and key regions and countries. This study considers the Rilpivirine value and volume generated from the sales of the...
  • エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の世界市場予測2019年-2024年
    LPI9070801 / LP Information / 2019年8月9日 / 「エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、1本/箱、3本/箱など、用途別には、病院、クリニック、ドラッグセンター、その他などに区分してまとめた調査レポートです。エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の世界市場概要（サマリー） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の企業別販売量・売上 ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の企業別市場シェア ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の世界市場規模：種類別（1本/箱、3本/箱） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の世界市場規模：用途別（病院、クリニック、ドラッグセンター、その他） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の米州市場規模（アメリカ、カナダ、メキシコなど） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・エルビテグラビル/コビシスタット/エムトリシタビン/テノフォビルアラフェナミド配合剤の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug market by product type, application, key manufacturers and key regions and countries. This study considers the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir...
  • ドルテグラビルの世界市場予測2019年-2024年
    LPI9070714 / LP Information / 2019年8月9日 / 「ドルテグラビルの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、10mg錠、50mg錠など、用途別には、HIV感染、その他などに区分してまとめた調査レポートです。ドルテグラビルのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・ドルテグラビルの世界市場概要（サマリー） ・ドルテグラビルの企業別販売量・売上 ・ドルテグラビルの企業別市場シェア ・ドルテグラビルの世界市場規模：種類別（10mg錠、50mg錠） ・ドルテグラビルの世界市場規模：用途別（HIV感染、その他） ・ドルテグラビルの米州市場規模（アメリカ、カナダ、メキシコなど） ・ドルテグラビルのアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・ドルテグラビルの欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・ドルテグラビルの中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Dolutegravir market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Dolutegravir business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Dolutegravir market by product type, application, key manufacturers and key regions and countries. This study considers the Dolutegravir value and volume generated from the sales of the...
  • ドルテグラビルナトリウムの世界市場予測2019年-2024年
    LPI9070715 / LP Information / 2019年8月9日 / 「ドルテグラビルナトリウムの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、ボトル包装、フィルムコーティング包装など、用途別には、成人エイズ患者、12歳以上子供エイズ患者などに区分してまとめた調査レポートです。ドルテグラビルナトリウムのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・ドルテグラビルナトリウムの世界市場概要（サマリー） ・ドルテグラビルナトリウムの企業別販売量・売上 ・ドルテグラビルナトリウムの企業別市場シェア ・ドルテグラビルナトリウムの世界市場規模：種類別（ボトル包装、フィルムコーティング包装） ・ドルテグラビルナトリウムの世界市場規模：用途別（成人エイズ患者、12歳以上子供エイズ患者） ・ドルテグラビルナトリウムの米州市場規模（アメリカ、カナダ、メキシコなど） ・ドルテグラビルナトリウムのアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・ドルテグラビルナトリウムの欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・ドルテグラビルナトリウムの中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Dolutegravir Sodium market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Dolutegravir Sodium business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Dolutegravir Sodium market by product type, application, key manufacturers and key regions and countries. This study considers the Dolutegravir Sodium value and volume generated from...
  • 抗HIV薬の世界市場予測2019年-2024年
    LPI9070111 / LP Information / 2019年8月9日 / 「抗HIV薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、処方薬、非処方薬など、用途別には、薬局、病院などに区分してまとめた調査レポートです。抗HIV薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・抗HIV薬の世界市場概要（サマリー） ・抗HIV薬の企業別販売量・売上 ・抗HIV薬の企業別市場シェア ・抗HIV薬の世界市場規模：種類別（処方薬、非処方薬） ・抗HIV薬の世界市場規模：用途別（薬局、病院） ・抗HIV薬の米州市場規模（アメリカ、カナダ、メキシコなど） ・抗HIV薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど） ・抗HIV薬の欧州市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど） ・抗HIV薬の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）... According to this study, over the next five years the Anti-AIDs Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Anti-AIDs Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Anti-AIDs Drug market by product type, application, key manufacturers and key regions and countries. This study considers the Anti-AIDs Drug value and volume generated from...
  • 膣炎薬の世界市場予測2019年-2024年
    LPI9072397 / LP Information / 2019年8月20日 / 「膣炎薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、Rx、 OTCなど、用途別には、病院、薬局、その他などに区分してまとめた調査レポートです。膣炎薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向、販売チャネルなどの情報が含まれています。 ・膣炎薬の世界市場概要（サマリー） ・膣炎薬の企業別販売量・売上 ・膣炎薬の企業別市場シェア ・膣炎薬の世界市場規模：種類別（Rx、 OTC） ・膣炎薬の世界市場規模：用途別（病院、薬局、その他） ・膣炎薬の米州市場規模（アメリカ、カナダ、メキシコなど） ・膣炎薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. According to this study, over the next five years the Vaginosis Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Vaginosis Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares,...

    • ◆H&Iグローバルリサーチのお客様（例）◆